News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Biogen Idec, Inc. (Massachusetts) Reports Third Quarter 2005 Results
October 27, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2005--Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader with leading products and capabilities in oncology, neurology and immunology, today reported its third quarter 2005 results.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Biogen
MORE ON THIS TOPIC
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
September 17, 2026
·
2 min read
·
Michael Gibney
Deals
Fed rate hike won’t hold biotech down despite climbing capital costs
September 17, 2026
·
2 min read
·
Annalee Armstrong
Neuroscience
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
September 17, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Roche bets up to $1B to advance next-gen bispecifics with Dualitas
September 17, 2026
·
1 min read
·
Tristan Manalac
